Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...
A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...
A Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a ...
Zydus introduces biosimilar denosumab 120 mg SC – protecting bone health in cancer patients: Our Bureau, Mumbai Wednesday, December 10, 2025, 13:30 Hrs [IST] Zydus Lifesciences ...
News-Medical.Net on MSN
Metabolic imaging enables early response prediction in bone-dominant metastatic breast cancer
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...
Zydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer patients. Priced at Rs 12,495, the drug aims to improve access ...
An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring ...
Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback